Comprehensive Financial Consultants Institutional, Inc. Lineage Cell Therapeutics, Inc. Transaction History

Comprehensive Financial Consultants Institutional, Inc.

  • $259 Million
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 11, 2022
SELL
$1.21 - $2.48 $6 - $12
-5 Closed
0 $0
Q4 2021

Mar 10, 2022
BUY
$1.84 - $2.68 $9 - $13
5 New
5 $0

Others Institutions Holding LCTX

# of Institutions
121
Shares Held
94.2M
Call Options Held
63.8K
Put Options Held
1K
View Full List

About Lineage Cell Therapeutics, Inc.

LCTX Quotes by TradingView
  • Ticker LCTX
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 169,755,008
  • Market Cap $102M
  • Description
  • Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...
More about LCTX
Track This Portfolio

Track Comprehensive Financial Consultants Institutional, Inc. Portfolio

Follow Comprehensive Financial Consultants Institutional, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Comprehensive Financial Consultants Institutional, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Comprehensive Financial Consultants Institutional, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email